Prot #CMBG453B12301: A Randomized, Double-Blind, Placebo-Controlled Phase III Multi-Center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as per IPSS-R, or

Project: Research project

Project Details

StatusActive
Effective start/end date6/25/20 → 7/31/28

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CMBG453B12301)